In the article by Minshall et al, “Potentiation of the Actions of Bradykinin by Angiotensin I-Converting Enzyme Inhibitors: The Role of Expressed Human Bradykinin B2 Receptors and Angiotensin I-Converting Enzyme in CHO Cells” (Circ Res. 1997;81:848-856), paragraph 2 of page 855 should read as follows: Even if ACE expression is relatively low, the inhibitor still potentiates BK. Because in cotransfection experiments ACE was expressed in lower concentration than B2 receptor, we carried out experiments to determine whether this would influence the results (B. Marcic, S. Danilov, P. Deddish, F. Tan, E.G. Erdös, unpublished data). In those experiments, we did not use the coexpression system, but we sequentially transfected the cells first with full-size cDNA for ACE. By clonal selection, cells with high ACE activity were transfected with B2 receptor cDNA. The experiments reversed the molar ratio between the ACE and the B2 receptor molecule to 5:1, but enalaprilat potentiated BK the same way as before, established by measuring arachidonic acid release.
- © 1998 American Heart Association, Inc.